Many people using semaglutide for weight loss hit a plateau after several months. The scale stops moving even though appetite suppression continues. AOD-9604, a peptide fragment of human growth hormone, is increasingly discussed as an add-on for stubborn fat. This article compares their mechanisms, examines whether they can work together, and sets realistic expectations for fat loss after a GLP-1 plateau.
Semaglutide is a GLP-1 receptor agonist. It lowers blood glucose, slows gastric emptying, and reduces appetite through central nervous system effects. Weight loss from semaglutide averages 10 to 15 percent of body weight in clinical trials. AOD-9604 is a modified fragment of growth hormone (amino acids 177-191) that has been studied for its lipolytic, or fat releasing, activity without the growth effects of full growth hormone.
How semaglutide and AOD-9604 differ in fat loss mechanisms
Semaglutide reduces fat indirectly by lowering caloric intake. It does not directly signal fat cells to release stored triglycerides. AOD-9604, by contrast, was designed to mimic the lipolytic region of growth hormone. A 1999 study in obese Zucker rats found that AOD-9604 reduced body fat without affecting blood glucose or insulin. Human trials have been small and mixed.
A 2002 clinical trial in obese adults reported that AOD-9604 produced modest fat loss over 12 weeks compared to placebo. The effect was smaller than what semaglutide achieves through appetite suppression. The key difference is that semaglutide works on energy intake, while AOD-9604 targets fat oxidation and lipolysis. This mechanistic separation is why some researchers see potential for stacking.
- Semaglutide: reduces appetite, slows gastric emptying, improves insulin sensitivity.
- AOD-9604: stimulates lipolysis, may increase fat oxidation, does not raise blood sugar.
- Both: require a calorie deficit for meaningful fat loss; neither is a standalone miracle.
Can AOD-9604 break a semaglutide plateau?
A plateau on semaglutide usually means the body has adapted to the lower calorie intake. Metabolic rate drops, and hunger signals may return. Adding AOD-9604 does not directly address appetite or metabolic adaptation. However, it may increase the rate at which stored fat is mobilised during a continued calorie deficit. This could translate to a small additional fat loss per week.
No published trial has tested the combination of semaglutide and AOD-9604 in humans. The evidence for synergy is theoretical. A 2005 review noted that AOD-9604's lipolytic effect is modest and most pronounced in animal models of obesity. Users should not expect the same magnitude of effect as semaglutide alone.
Outcomes described in studies cited here cannot be assumed to generalise to individual users.
For someone stuck at a semaglutide plateau, the first steps should be reassessing calorie intake, protein, and activity. AOD-9604 might be considered after those basics are optimised. It is not a replacement for semaglutide, nor does it reverse metabolic adaptation.
Dosing, administration, and practical considerations
Semaglutide is injected once weekly. Doses for weight loss start at 0.25 mg and increase to 2.4 mg. AOD-9604 is typically injected daily at 250 to 500 micrograms. It is often cycled for 8 to 12 weeks. The peptide is available as a lyophilised powder requiring reconstitution with bacteriostatic water.
Cost varies widely. Compounded semaglutide can run $200 to $400 per month. AOD-9604 from research chemical suppliers is cheaper, often under $100 per month. However, quality control is a concern. Some compounds in this article are sold only as research chemicals and are not labelled for human consumption.
- Semaglutide: weekly injection, prescription required, well studied.
- AOD-9604: daily injection, no prescription, limited human data.
- Stacking: no safety data; consider monitoring blood glucose and lipids.
What to watch for: side effects and monitoring
Semaglutide's side effects are well documented: nausea, vomiting, diarrhoea, constipation. AOD-9604 is generally well tolerated in small trials. Reported side effects include mild injection site reactions and occasional headache. Because AOD-9604 is a growth hormone fragment, there is theoretical concern about insulin resistance with long term use, but this has not been shown in human studies.
Anyone combining these should monitor fasting glucose and HbA1c. Semaglutide lowers glucose, while AOD-9604's effect on glucose is neutral to slightly positive. The net effect is likely safe, but individual responses vary. A 2003 study found no adverse metabolic effects from AOD-9604 in obese subjects over 12 weeks.
For a deeper comparison of these two compounds for stubborn fat, see Semaglutide vs. AOD-9604 for Stubborn Fat: Which One Actually Works?.
Realistic expectations for fat loss after a plateau
After losing 10 to 15 percent of body weight on semaglutide, further loss slows. Adding AOD-9604 might yield an extra 1 to 2 pounds of fat loss per month, based on extrapolation from small trials. That is meaningful over six months but not dramatic. The bigger lever remains diet and activity.
Some users report that AOD-9604 helps with stubborn areas like the abdomen and thighs. This is plausible because growth hormone fragments preferentially mobilise visceral and abdominal fat in some studies. However, spot reduction is not supported by strong evidence. Fat loss pattern is largely genetic.
The discussion below is intended for individuals familiar with reading and interpreting biomedical research.
Common questions
Can I take AOD-9604 with semaglutide?
There are no published safety studies on this combination. Mechanistically, they act on different pathways: semaglutide on appetite and glucose, AOD-9604 on lipolysis. A cautious approach would start with low doses of each and monitor blood glucose. Consult a clinician familiar with peptides before combining.
How long does it take for AOD-9604 to work?
In clinical trials, measurable fat loss occurred after 8 to 12 weeks of daily dosing. Some users report visible changes sooner, but this is anecdotal. AOD-9604 is not a rapid fat burner. It works gradually by increasing the rate of fat oxidation during a calorie deficit.
Is AOD-9604 a replacement for semaglutide?
No. Semaglutide reduces food intake, which is the primary driver of weight loss. AOD-9604 does not suppress appetite. If you stop semaglutide and use only AOD-9604, you will likely regain weight unless you maintain a strict diet. AOD-9604 is best viewed as an adjunct, not a substitute.
What is the best way to break a semaglutide plateau?
First, recalculate your calorie needs at your new lower body weight. Increase protein to preserve muscle. Add resistance training if not already doing so. Consider a diet break of 1 to 2 weeks at maintenance calories. Only after these steps would adding a lipolytic peptide like AOD-9604 be reasonable.